查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813461

2032 年癌症倖存者管理市場預測：按組件、部署模式、癌症類型、最終用戶和地區進行的全球分析

Cancer Survivorship Management Market Forecasts to 2032 - Global Analysis By Component (Services, Software & Digital Platforms and Other Components), Deployment Mode, Cancer Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球癌症生存管理市場預計在 2025 年達到 22.9 億美元，預計到 2032 年將達到 44.8 億美元，預測期內的複合年成長率為 10.0%。

癌症存活管理是一種結構化的多學科護理，從確診到治療後，為患者提供持續的照顧。該護理包括復發監測、治療的長期和長期影響管理、促進身心健康以及協調後續護理。此方法也應對社會、經濟和生活方式方面的挑戰，同時為看護者提供支持。生存計畫旨在恢復生活品質，促進患者重返社會，並確保醫療保健提供者提供持續的照顧。

根據《血液學與腫瘤學雜誌》報道，到2021年，癌症將佔全球男性和女性死亡人數的14.57%，佔總傷殘調整生命年（DALY）的8.8%。年齡標準化發生率（ASIR）為每10萬人790.33例，其中女性的ASIR高於男性（923.44 vs. 673.09），而男性的年齡標準化死亡率（ASDR）更高（145.69 vs. 93.60），這凸顯了製定性別敏感的癌症控制策略的必要性。

提高對近期和長期影響的認知

醫療保健提供者如今優先考慮長期監測和復健策略，以應對疲勞、認知能力下降和繼發性惡性腫瘤等問題。這種轉變推動了對超越急性護理的綜合生存護理計劃的需求。此外，數據分析和病患登記系統的進步使得更好地追蹤存活結果成為可能，並促進了循證干預措施的實施。隨著全球存活率的提高，結構化追蹤護理的需求正成為腫瘤服務的核心重點。

護理分散且不協調，報銷不足

倖存者經常在缺乏集中護理協調的專家之間輾轉，導致症狀管理和心理社會支持方面存在差異。不同地區的倖存者服務報銷政策不一致，阻礙了醫療機構投資於綜合計畫。此外，缺乏標準化的長期追蹤通訊協定也導致了護理品質的差異。這些機構效率低下的問題阻礙了倖存者模式的擴充性，並減緩了市場擴張。

專注於預防和健康計劃

融合營養諮詢、身體復健、心理健康支持和生活方式調整的項目越來越受歡迎。數位平台和行動醫療應用程式促進了個人化的健康追蹤，使倖存者能夠積極管理自己的康復情況。此外，雇主和保險公司也擴大支持倖存者健康舉措，以降低長期醫療成本。這種積極主動的方法正在將倖存者照護從被動治療轉變為促進整體健康。

治療抵抗和勞動力短缺

某些癌症治療方案的抗藥性正在出現，對有效的生存管理構成威脅，尤其是在需要長期治療的病例中。隨著癌症類型的演變和日益複雜，對專業後續護理的需求也日益成長。然而，訓練有素的腫瘤學專業人員和生存護理專家的短缺正給醫療保健系統帶來巨大壓力。農村和服務欠缺地區尤其脆弱，難以獲得多學科團隊的幫助。這種需求和人力的不平衡可能會危及生存服務的品質和範圍。

COVID-19的影響：

由於醫療系統優先考慮緊急應變，COVID-19疫情擾亂了常規癌症治療，包括癌症倖存者服務。許多倖存者的後續預約、篩檢和復健治療都遭遇延誤，導致焦慮加劇，症狀難以控制。同時，這場危機加速了遠端醫療和遠端監控工具的普及，這些工具如今已成為癌症倖存者照護的必需品。虛擬支援小組和數位護理協調平台應運而生，填補了這些空白，在封鎖期間提供了持續的護理。

服務業預計將成為預測期內最大的產業

預計服務領域將在預測期內佔據最大市場佔有率，這得益於其提供全面的諮詢、康復、營養支持和長期監測服務。這些服務對於滿足倖存者從身體康復到心理健康等多方面的需求至關重要。醫院和專科診所正在擴展倖存者計劃，以納入由電子健康記錄和患者參與工具支援的個人化護理途徑。

預計骨髓惡性腫瘤領域在預測期內將達到最高複合年成長率

預計骨髓惡性腫瘤領域將在預測期內達到最高成長率。由於復發和免疫系統併發症的風險較高，白血病、淋巴瘤和骨髓瘤的倖存者通常需要在治療後接受密切監測。標靶治療和幹細胞移植的創新提高了生存率，增加了對計劃生存護理的需求。此外，對長期血液毒性和繼發性癌症的研發正在推動專門的追蹤通訊協定的發展，進一步推動該領域的成長。

佔比最高的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於其龐大的患者群體和不斷擴展的醫療基礎設施。中國、印度和日本等國家正大力投資腫瘤服務，包括整合存活期照護。公共衛生宣傳活動和政府資助的措施正在提高人們對治療後支持的認知，而私人醫療機構也在推出專為癌症倖存者量身定做的健康中心。

複合年成長率最高的地區：

預計北美在預測期內的複合年成長率最高，這得益於其先進的醫療保健體系和以患者為中心的醫療服務。美國和加拿大在實施生存照顧計畫方面處於主導，並得到了政策框架和報銷模式的支持。學術機構和癌症中心正在進行關於存活結果的開創性研究，影響臨床指南和治療標準。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球癌症倖存者管理市場（按組成部分）

  • 服務
    • 後續行動和監測
    • 症狀管理
    • 社會心理與心理健康支持
    • 營養諮詢
    • 身體復健和運動計劃
    • 生育治療和性健康管理
  • 軟體和數位平台
    • 帶有重要模組的電子健康記錄（EHR）
    • 患者門戶網站和行動應用程式
    • 護理協調和導航工具
    • 遠端醫療和遠端監控解決方案
  • 其他組件

6. 全球癌症生存管理市場（依部署模式）

  • 雲端基礎/SaaS
  • 本地部署
  • 混合

7. 全球癌症生存管理市場（按癌症類型）

  • 乳癌
  • 攝護腺癌
  • 大腸直腸癌
  • 造血系統惡性腫瘤
  • 其他癌症類型

8. 全球癌症倖存者管理市場（按最終用戶）

  • 醫院和癌症中心
  • 門診手術中心（ASC）
  • 居家照護環境
  • 專科診所
  • 其他最終用戶

9. 全球癌症倖存者管理市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Elekta AB
  • Accuray Incorporated
  • Varian Medical Systems
  • Philips Healthcare
  • GE Healthcare
  • Roche
  • Novartis AG
  • Bristol-Myers Squibb（BMS）
  • Pfizer Inc.
  • Johnson & Johnson
  • Guardant Health
  • Illumina
  • McKesson Corporation
  • Allscripts Healthcare Solutions, Inc.
  • Epic Systems Corporation
  • Cerner Corporation
  • Carevive Systems
  • Cordata Healthcare Innovations
Product Code: SMRC30910

According to Stratistics MRC, the Global Cancer Survivorship Management Market is accounted for $2.29 billion in 2025 and is expected to reach $4.48 billion by 2032 growing at a CAGR of 10.0% during the forecast period. Cancer survivorship management is the structured, multidisciplinary care provided to individuals from the point of diagnosis through post-treatment life. It encompasses monitoring for recurrence, managing long-term and late effects of therapy, promoting physical and psychological well-being, and coordinating follow-up care. This approach also addresses social, financial, and lifestyle challenges while supporting caregivers. Survivorship plans aim to restore quality of life, facilitate reintegration, and ensure continuity of care across healthcare providers

According to Journal of Hematology & Oncology, cancer accounted for 14.57% of global deaths and 8.8% of total disability-adjusted life years (DALYs) in 2021 across both sexes. The age-standardized incidence rate (ASIR) was 790.33 per 100,000, with females exhibiting higher ASIR than males (923.44 vs. 673.09), while males showed higher age-standardized death rates (ASDR) (145.69 vs. 93.60), underscoring the need for gender-sensitive cancer control strategies.

Market Dynamics:

Driver:

Growing recognition of late and long-term effects

Healthcare providers are now prioritizing long-term monitoring and rehabilitation strategies to address issues such as fatigue, cognitive decline, and secondary malignancies. This shift is driving demand for integrated survivorship care plans that extend beyond acute treatment. Moreover, advancements in data analytics and patient registries are enabling better tracking of survivorship outcomes, fostering evidence-based interventions. As survivorship rates improve globally, the need for structured follow-up care is becoming a central focus in oncology services.

Restraint:

Fragmented and uncoordinated care, inadequate reimbursement

Survivors often navigate multiple specialists without cohesive care coordination, leading to gaps in symptom management and psychosocial support. Reimbursement policies for survivorship services remain inconsistent across regions, discouraging providers from investing in comprehensive programs. Additionally, the lack of standardized protocols for long-term follow-up contributes to variability in care quality. These systemic inefficiencies hinder the scalability of survivorship models and slow down market expansion.

Opportunity:

Driving focus on preventative and wellness programs

Programs that incorporate nutrition counseling, physical rehabilitation, mental health support, and lifestyle modification are gaining traction. Digital platforms and mobile health applications are facilitating personalized wellness tracking, empowering survivors to actively manage their recovery. Furthermore, employers and insurers are increasingly supporting survivorship wellness initiatives to reduce long-term healthcare costs. This proactive approach is reshaping survivorship care from reactive treatment to holistic health promotion.

Threat:

Therapeutic resistance & workforce shortages

Emerging resistance to certain cancer therapies poses a threat to effective survivorship management, particularly in cases requiring prolonged treatment. As cancer types evolve and become more complex, the need for specialized follow-up care intensifies. However, a shortage of trained oncology professionals and survivorship care specialists is straining healthcare systems. Rural and underserved regions are especially vulnerable, with limited access to multidisciplinary teams. This imbalance between demand and workforce capacity may compromise the quality and reach of survivorship services.

Covid-19 Impact:

The COVID-19 pandemic disrupted routine cancer care, including survivorship services, as healthcare systems prioritized emergency response. Many survivors experienced delays in follow-up appointments, screenings, and rehabilitation therapies, leading to increased anxiety and unmanaged symptoms. On the other hand, the crisis accelerated the adoption of telehealth and remote monitoring tools, which have now become integral to survivorship care. Virtual support groups and digital care coordination platforms emerged to fill the gap, offering continuity of care during lockdowns.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period due to its comprehensive offerings, including counseling, rehabilitation, nutritional support, and long-term monitoring. These services are essential for addressing the multifaceted needs of survivors, ranging from physical recovery to emotional well-being. Hospitals and specialty clinics are expanding survivorship programs to include personalized care pathways, supported by electronic health records and patient engagement tools.

The hematologic malignancies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hematologic malignancies segment is predicted to witness the highest growth rate. Survivors of leukemia, lymphoma, and myeloma often require intensive post-treatment surveillance due to high relapse risks and immune system complications. Innovations in targeted therapies and stem cell transplantation have improved survival rates, thereby increasing the demand for structured survivorship care. Additionally, research into long-term hematologic toxicity and secondary cancers is driving the development of specialized follow-up protocols, boosting segment growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to its vast patient population and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology services, including survivorship care integration. Public health campaigns and government-backed initiatives are raising awareness about post-treatment support, while private providers are launching wellness centers tailored for cancer survivors.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by its advanced healthcare systems and strong focus on patient-centered care. The U.S. and Canada are leading in the implementation of survivorship care plans, supported by policy frameworks and reimbursement models. Academic institutions and cancer centers are pioneering research on survivorship outcomes, influencing clinical guidelines and care standards.

Key players in the market

Some of the key players in Cancer Survivorship Management Market include Elekta AB, Accuray Incorporated, Varian Medical Systems, Philips Healthcare, GE Healthcare, Roche, Novartis AG, Bristol-Myers Squibb (BMS), Pfizer Inc., Johnson & Johnson, Guardant Health, Illumina, McKesson Corporation, Allscripts Healthcare Solutions, Inc., Epic Systems Corporation, Cerner Corporation, Carevive Systems, and Cordata Healthcare Innovations.

Key Developments:

In July 2025, Novartis announced regulatory approval for the first malaria medicine for newborns and young infants (Coartem(R) baby), marking an important pediatric milestone. The company noted expectation of rapid regulatory approvals in several African countries under a special global pathway. Novartis framed the approval as expanding access for vulnerable, very young patients.

In July 2025, Illumina launched the next generation of TruSight Oncology 500 (announced July 30, 2025), a comprehensive genomic profiling assay for cancer research. The product release highlighted expanded genomic coverage to support research and clinical trial workflows.

In May 2025, Roche announced FDA approval of the VENTANA(R) MET (SP44) RxDx Assay - the first companion diagnostic approved to assess MET protein expression in certain non-small cell lung cancers. The approval enables patient selection for AbbVie's c-Met targeted therapy (Emrelis(TM)) and supports precision oncology pathways.

Components Covered:

  • Services
  • Software & Digital Platforms
  • Other Components

Deployment Modes Covered:

  • Cloud-based / SaaS
  • On-premises
  • Hybrid

Cancer Types Covered:

  • Breast
  • Prostate
  • Colorectal
  • Hematologic malignancies
  • Other Cancer Types

End Users Covered:

  • Hospitals and Cancer Centers
  • Ambulatory Surgical Centers (ASCs)
  • Homecare Settings
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Survivorship Management Market, By Component

  • 5.1 Introduction
  • 5.2 Services
    • 5.2.1 Follow-up & Surveillance
    • 5.2.2 Symptom Management
    • 5.2.3 Psychosocial & Mental Health Support
    • 5.2.4 Nutritional Counseling
    • 5.2.5 Physical Rehabilitation & Exercise Programs
    • 5.2.6 Fertility & Sexual Health Management
  • 5.3 Software & Digital Platforms
    • 5.3.1 Electronic Health Records (EHR) with Survivorship Modules
    • 5.3.2 Patient Portals & Mobile Apps
    • 5.3.3 Care Coordination & Navigation Tools
    • 5.3.4 Telehealth & Remote Monitoring Solutions
  • 5.4 Other Components

6 Global Cancer Survivorship Management Market, By Deployment Mode

  • 6.1 Introduction
  • 6.2 Cloud-based / SaaS
  • 6.3 On-premises
  • 6.4 Hybrid

7 Global Cancer Survivorship Management Market, By Cancer Type

  • 7.1 Introduction
  • 7.2 Breast
  • 7.3 Prostate
  • 7.4 Colorectal
  • 7.5 Hematologic malignancies
  • 7.6 Other Cancer Types

8 Global Cancer Survivorship Management Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Cancer Centers
  • 8.3 Ambulatory Surgical Centers (ASCs)
  • 8.4 Homecare Settings
  • 8.5 Specialty Clinics
  • 8.6 Other End Users

9 Global Cancer Survivorship Management Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Elekta AB
  • 11.2 Accuray Incorporated
  • 11.3 Varian Medical Systems
  • 11.4 Philips Healthcare
  • 11.5 GE Healthcare
  • 11.6 Roche
  • 11.7 Novartis AG
  • 11.8 Bristol-Myers Squibb (BMS)
  • 11.9 Pfizer Inc.
  • 11.10 Johnson & Johnson
  • 11.11 Guardant Health
  • 11.12 Illumina
  • 11.13 McKesson Corporation
  • 11.14 Allscripts Healthcare Solutions, Inc.
  • 11.15 Epic Systems Corporation
  • 11.16 Cerner Corporation
  • 11.17 Carevive Systems
  • 11.18 Cordata Healthcare Innovations

List of Tables

  • Table 1 Global Cancer Survivorship Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Cancer Survivorship Management Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global Cancer Survivorship Management Market Outlook, By Services (2024-2032) ($MN)
  • Table 4 Global Cancer Survivorship Management Market Outlook, By Follow-up & Surveillance (2024-2032) ($MN)
  • Table 5 Global Cancer Survivorship Management Market Outlook, By Symptom Management (2024-2032) ($MN)
  • Table 6 Global Cancer Survivorship Management Market Outlook, By Psychosocial & Mental Health Support (2024-2032) ($MN)
  • Table 7 Global Cancer Survivorship Management Market Outlook, By Nutritional Counseling (2024-2032) ($MN)
  • Table 8 Global Cancer Survivorship Management Market Outlook, By Physical Rehabilitation & Exercise Programs (2024-2032) ($MN)
  • Table 9 Global Cancer Survivorship Management Market Outlook, By Fertility & Sexual Health Management (2024-2032) ($MN)
  • Table 10 Global Cancer Survivorship Management Market Outlook, By Software & Digital Platforms (2024-2032) ($MN)
  • Table 11 Global Cancer Survivorship Management Market Outlook, By Electronic Health Records (EHR) with Survivorship Modules (2024-2032) ($MN)
  • Table 12 Global Cancer Survivorship Management Market Outlook, By Patient Portals & Mobile Apps (2024-2032) ($MN)
  • Table 13 Global Cancer Survivorship Management Market Outlook, By Care Coordination & Navigation Tools (2024-2032) ($MN)
  • Table 14 Global Cancer Survivorship Management Market Outlook, By Telehealth & Remote Monitoring Solutions (2024-2032) ($MN)
  • Table 15 Global Cancer Survivorship Management Market Outlook, By Other Components (2024-2032) ($MN)
  • Table 16 Global Cancer Survivorship Management Market Outlook, By Deployment Mode (2024-2032) ($MN)
  • Table 17 Global Cancer Survivorship Management Market Outlook, By Cloud-based / SaaS (2024-2032) ($MN)
  • Table 18 Global Cancer Survivorship Management Market Outlook, By On-premises (2024-2032) ($MN)
  • Table 19 Global Cancer Survivorship Management Market Outlook, By Hybrid (2024-2032) ($MN)
  • Table 20 Global Cancer Survivorship Management Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 21 Global Cancer Survivorship Management Market Outlook, By Breast (2024-2032) ($MN)
  • Table 22 Global Cancer Survivorship Management Market Outlook, By Prostate (2024-2032) ($MN)
  • Table 23 Global Cancer Survivorship Management Market Outlook, By Colorectal (2024-2032) ($MN)
  • Table 24 Global Cancer Survivorship Management Market Outlook, By Hematologic malignancies (2024-2032) ($MN)
  • Table 25 Global Cancer Survivorship Management Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 26 Global Cancer Survivorship Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Cancer Survivorship Management Market Outlook, By Hospitals and Cancer Centers (2024-2032) ($MN)
  • Table 28 Global Cancer Survivorship Management Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 29 Global Cancer Survivorship Management Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 30 Global Cancer Survivorship Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 31 Global Cancer Survivorship Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.